| [Development of immunotherapy against HER2/neu: hydrophobized polysaccharides/oncoprotein complexes and human dendritic cells]. | None |
| The N-terminal common domain of simian virus 40 large T and small t antigens acts as a transformation suppressor of the HER-2/neu oncogene. | None |
| Oncogenic signals of HER-2/neu in regulating the stability of the cyclin-dependent kinase inhibitor p27. | None |
| Role of HER-2/neu oncogene amplification in determination of outcome of patients with cancer. | None |
| Sebaceous carcinoma of the eyelids: frequent expression of c-erbB-2 oncoprotein. | None |
| The HER-2/neu oncogene in tumors of the gastrointestinal tract. | None |
| Salivary duct carcinoma--a highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression. | None |
| Serum CA 125 as a tumor marker and the expression of c-erbB-2 oncogene in tubal malignancies. | None |
| Multiparameter flow cytometric measurement of epidermal growth factor receptor and c-erbB-2 oncoprotein in cultured cells and in fresh and preserved solid tumor cells. | None |
| Cancer vaccines targeting the HER2/neu oncogenic protein. | None |
| [In vitro cleavage action of c-erbB-2 oncogene-specific ribozyme]. | None |
| [Expression of C-erbB-2 oncogene mRNA in salivary gland tumors]. | None |
| Adenovirus targeting to c-erbB-2 oncoprotein by single-chain antibody fused to trimeric form of adenovirus receptor ectodomain. | None |
| [Significance of expression of epidermal growth factor receptor, transforming growth factor beta, c-erbB-2 oncogene in myoepithelioma of salivary gland]. | None |
| Generation of monoclonal antibody CIBCgp185 against C-erbB-2 oncoprotein and its clinical evaluation. | None |
| Vaccination against the HER-2/neu oncogenic protein. | None |
| Preventive efficacy of receptor class selective retinoids on HER-2/neu oncogene expressing preneoplastic human mammary epithelial cells. | None |
| C-erbB2 oncoprotein and its soluble ectodomain: a new potential tumor marker for prognosis early detection and monitoring patients undergoing Herceptin treatment. | None |
| Oncogenic Ras/Her-2 mediate hyperproliferation of polarized epithelial cells in 3D cultures and rapid tumor growth via the PI3K pathway. | None |
| Oncogenic Ras/Her-2 mediate hyperproliferation of polarized epithelial cells in 3D cultures and rapid tumor growth via the PI3K pathway. | None |